Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of the Planned Treatment Period in the AL002-2 study.~* The participant is willing and able to give informed consent.~* Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week~Exclusion Criteria:~* Participants deemed not able to provide consent or assent by the Investigator or by local regulations.~* Participants who were prematurely and permanently discontinued from treatment in the parent study for safety reasons.~* Participation deemed inappropriate per Investigator discretion.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- AL002 Dose 1 (Type: EXPERIMENTAL): AL002 every 4 weeks
- AL002 Dose 2 (Type: EXPERIMENTAL): AL002 every 4 weeks
- AL002 Dose 3 (Type: EXPERIMENTAL): AL002 every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).